New antibody therapy stopped tumor growth and blocked spread in treatment-resistant triple-negative breast cancer models.
Pharmaceutical Technology on MSN
Harbour BioMed and BMS sign multi-specific antibody collab
Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...
Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...
Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...
After the government’s endorsement, many parents rushed to get their hands on leucovorin. They soon discovered that they were ...
Researchers are striving to understand the impact a phenomenon known as original antigenic sin has on immunity to the virus.
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of ...
("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized ...
A recently approved injectable eczema drug, Nemluvio, provides quick itch relief to patients with the maddening skin disease, ...
GMT] In this webinar, presented in association with the journal mAbs, Drs. Crescioli and Reichert discuss recent trends in ...
PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...
Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback